T cell engagers are an exciting area of immunotherapy that remains in the early innings of development. We believe gamma-delta T cells offer unique properties, including tissue residence, phagocytosis ...

The Parker Institute for Cancer Immunotherapy (PICI) today announced the appointment of Karen E. Knudsen, MBA PhD as its new ...

On May 21, 2024, the Company announced that the U.S. Food and Drug Administration (FDA) provided clearance for the Company’s investigational new drug (IND) application to proceed with a Phase 1 ...